Cui 2017.

Methods	Study design: randomised clinical trial Study duration: November 2014 to November 2016 Duration of follow‐up: 2 months Setting: hospital
Participants	Inclusion criteria: diagnosed as HCC by pathology Exclusion criteria: intrahepatic disseminated tumours; with electrolyte imbalance; with arrhythmia; with contraindications for intervention therapy Age (mean ± SD, range): TACE + RFA: 63.1 ± 6.9 years, 51‐76 years; TACE alone: 62.3 ± 6.5 years, 50‐76 years Male (n/total): TACE + RFA: 27/43; TACE alone: 26/43
Interventions	TACE + RFA group (n = 43): TACE: chemotherapeutic drugs: cisplatin 80 mg, epirubicin 30 mg, and theprubicin 30 mg RFA: The interval between TACE and RFA was two weeks. RADIONICS system. Output power of 40 W. Fifteen minutes per RFA application TACE group (n = 43): Chemotherapeutic drugs: cisplatin 80 mg, epirubicin 30 mg, and theprubicin 30 mg
Outcomes	Tumour response: measured by contrast‐enhanced images at 2 months after treatment Serum level of CD3+ cell, CD4/CD8, NK cell, and TNF‐α。 Serum level of AFP, CA199, and GGT
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.